Clinical Trials Logo

Filter by:
NCT ID: NCT05854264 Recruiting - Clinical trials for Microbial Colonization

Influence of Nutrition on Lung Microbiota in Traumatic Brain Injury

Microbiota
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Role of immunonutrition in modulating the lung microbiota of intubated TBJ patients and how this interaction may affect the infections and outcomes. For these reasons, the aims of our study are the evaluation of the impact of immunonutrition on the lung microbiota and the relationship between lung microbiota and infection in TBJ patients in ICU.

NCT ID: NCT05853692 Recruiting - Oral Mucositis Clinical Trials

Prevention of Oral Mucositis in Head and Neck Cancer.

OMHNC-1
Start date: October 10, 2022
Phase: N/A
Study type: Interventional

Oral Mucositis (OM) consists in the painful inflammation and ulceration of the mucous membranes lining the digestive tract, lasting between 7 and 98 days; and starts as an acute inflammation of oral mucosa, tongue, and pharynx after RT exposure. Gel X spray is a product based on zinc gluconate. It could be helpful to achieve the prevention of Oral Mucositis and, in case of OM manifestation, the reduction of oral pain symptoms and to accelerate the healing process of oral mucositis ulcerations. The aim of this study is to demonstrate the efficacy of the treatment with Gel X to reduce the incidence of oral mucositis, in comparison with Sodium Bicarbonate.

NCT ID: NCT05853575 Recruiting - Metastatic Cancer Clinical Trials

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

NCT ID: NCT05853419 Recruiting - Coronary Disease Clinical Trials

Change History and Adopt a Robotic SolutioN for anGioplasty procedurE

CHANGE
Start date: June 20, 2023
Phase:
Study type: Observational [Patient Registry]

The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.

NCT ID: NCT05853302 Recruiting - Clinical trials for Adrenalectomy; Status

Robot-assisted vs Laparoscopic Lateral Transabdominal Adrenalectomy

RvsL-TLA
Start date: December 15, 2022
Phase:
Study type: Observational

This retrospective study evaluates the security and the effectiveness of robotic adrenalectomy when compared to laparoscopic approach in patients who underwent minimally-invasive lateral transperitoneal unilateral adrenalectomy.

NCT ID: NCT05853224 Recruiting - Dermal Filler Clinical Trials

An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel

Start date: April 2, 2022
Phase: N/A
Study type: Interventional

The aim of this interventional, pre-market, double- blinded, controlled, two stages study is to evaluate the performance and safety of Crosslinked Hyaluronic Acid (CLHA) Hydrogel (with and without Lidocaine) for the Treatment of Soft Tissue Deficits.

NCT ID: NCT05853198 Recruiting - Clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability

CASPER
Start date: December 29, 2022
Phase: N/A
Study type: Interventional

The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.

NCT ID: NCT05852691 Recruiting - Breast Cancer Clinical Trials

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).

NCT ID: NCT05852431 Recruiting - Clinical trials for Severe Hypertriglyceridemia

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

ENTRUST
Start date: June 15, 2023
Phase: Phase 3
Study type: Interventional

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

NCT ID: NCT05852223 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Pembrolizumab in High-risk Thyroid Cancer

NePenThe
Start date: April 2024
Phase: Phase 2
Study type: Interventional

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.